Pierre Gholam MD

@livermd.bsky.social

3 years ago

#Tremelimumab plus #Durvalumab in Unresectable Hepatocellular Carcinoma | NEJM Evidence #hcctwitter evidence.nejm.org/doi/full/10.1056/EVIDoa2...

Pierre Gholam MD

@livermd.bsky.social

3 years ago

Could third time be the charm for a Chinese manufactured IO drug? #camrelizumab apparently on track for ⁦@US_FDA⁩ review based on 1L Ph3 data in #HCC in combination with TKI #apatinib #HCCTwitter ...

Pierre Gholam MD

@livermd.bsky.social

3 years ago

Clinical characteristics, surveillance, treatment allocation, and outcomes of #NAFLD related #HCC great work by ⁦@DrLoomba⁩ ⁦@DrHuangDQ⁩ and colleagues #HCCtwitter www.thelancet.com/journals/lanonc/article/...

Pierre Gholam MD

@livermd.bsky.social

3 years ago

For those who tweet about all things #HCC can we copy from others and start tagging tweets with #HCCTwitter @NDP1001 @laurakulik1 @AnjanaPillaiMD @GIcancerDoc @GABOUALFA @DrElkhoueiry @bruixj @augustoNYC @pashtoonkasi @riadsalemIR @docamitgs @nicole_rich8 @jmarrero6713 @DanengLi